Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moake, J
Right arrow Articles by Pehta, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moake, J
Right arrow Articles by Pehta, J
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura

J Moake, M Chintagumpala, N Turner, P McPherson, L Nolasco, C Steuber, P Santiago-Borrero, M Horowitz and J Pehta

Baylor College of Medicine, Houston, TX.

Two children with congenital chronic relapsing thrombotic thrombocytopenic purpura (TTP) have episodes every 3 weeks. These relapses can be prevented by the infusion of normal fresh-frozen plasma (FFP) without concurrent plasmapheresis. We conducted a study to determine whether the exposure of normal plasma to agents that inactivate human immunodeficiency virus and other viruses destroys the component necessary for the effective treatment of this type of TTP that requires only plasma infusion to prevent or reverse relapses. Clinical responsiveness and von Willebrand factor (vWF)-mediated fluid shear stress-induced platelet aggregation were evaluated before and after the infusion of 10 mL/kg FFP or solvent [tri(n- butyl)phosphate]/detergent (Triton X-100)-treated plasma (S/D plasma). Platelet aggregation at shear stresses of 90 to 180 dyne/cm2 (similar to those in the partially occluded microcirculation) imposed for 30 seconds was excessive using the citrated platelet-rich plasma of both patients, and was associated with the presence of unusually large vWF forms in patient platelet-poor plasma. Infusion with either FFP or S/D plasma at 3-week intervals caused the platelet count to increase to (or above) normal within 1 week (on 12 of 12 occasions); the disappearance or diminution of unusually large vWF forms within 1 hour (on 6 of 10 occasions studied); and the reversal within 1 to 4 hours of excessive shear-induced platelet aggregation (on 8 of 9 occasions studied). We conclude that a component in normal plasma resistant to S/D treatment is responsible for preventing thrombocytopenia and TTP episodes, and for controlling excessive shear-induced aggregation in these patients. Our results suggest that excessive in vivo platelet aggregation in chronic relapsing TTP and excessive in vitro vWF-mediated shear-induced aggregation may be similar phenomena.

Volume 84, Issue 2, pp. 490-497, 07/15/1994
Copyright © 1994 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
NEJMHome page
J. L. Moake
Thrombotic Microangiopathies
N. Engl. J. Med., August 22, 2002; 347(8): 589 - 600.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Furlan and B. Lammle
Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura--new insights into underlying biochemical mechanisms
Nephrol. Dial. Transplant., August 1, 2000; 15(8): 1112 - 1114.
[Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
S L Allford and S J Machin
Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura
J. Clin. Pathol., July 1, 2000; 53(7): 497 - 501.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. GALBUSERA, A. BENIGNI, S. PARIS, P. RUGGENENTI, C. ZOJA, C. ROSSI, and G. REMUZZI
Unrecognized Pattern of von Willebrand Factor Abnormalities in Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura
J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1234 - 1241.
[Abstract] [Full Text]


Home page
NEJMHome page
J. L. Moake
Moschcowitz, Multimers, and Metalloprotease
N. Engl. J. Med., November 26, 1998; 339(22): 1629 - 1631.
[Full Text]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1994 by American Society of Hematology         Online ISSN: 1528-0020